Dr. Elizabeth Adams Joins Dairy Technical Services Team at Merck Animal Health

Summit, N.J., August 20, 2014 – Merck Animal Health today announced that Elizabeth Adams, D.V.M., has joined its Dairy Technical Services team. Prior to joining the company, Dr. Adams owned and operated an ambulatory dairy veterinary practice, as well as served as a veterinary consultant, providing herd health consultations on large dairies in Central Valley California.
A graduate of the University of California, Davis, School of Veterinary Medicine, Dr. Adams is known for her work in using ultrasound technology to assess lung damage that heifers may have experienced from early bouts of pneumonia, as well as evaluate bovine pregnancies and fetal sexing. Given her specialized knowledge in thoracic ultrasound techniques, Dr. Adams served as a speaker for Merck Animal Health, training other dairy practitioners in its use in calves. She also specializes in the use of microbiology diagnostics to evaluate milk quality.
A graduate of the University of California, Davis, School of Veterinary Medicine, Dr. Adams is known for her work in using ultrasound technology to assess lung damage that heifers may have experienced from early bouts of pneumonia, as well as evaluate bovine pregnancies and fetal sexing. Given her specialized knowledge in thoracic ultrasound techniques, Dr. Adams served as a speaker for Merck Animal Health, training other dairy practitioners in its use in calves. She also specializes in the use of microbiology diagnostics to evaluate milk quality.
A member of the American Association of Bovine Practitioners, Dr. Adams currently serves on the group’s animal welfare committee. In addition, she is a member of the Academy of Dairy Veterinary Consultants and served as its president from 2012 to 2013. Dr. Adams will provide technical support nationally but will focus primarily on western dairy operations.

About Merck Animal Health

Today’s Merck is a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn and Twitter at @MerckAH.

Merck Forward-Looking Statement

This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2012 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).